Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center. This evidence concerns the gene NR4A1 and breast carcinoma.